- World Pharma News Home » Conferences & Events » 4th Annual Biosimilars Conference ensuring qualitym safetym and perfomance of follow-on biologics
(a free service delivered by FeedBurner)
Visiongain is delighted to host the 4th Annual Biosimilars conference in Philadelphia this July. This 3-day event will provide you with practical insights into the scientific developments and regulatory challenges that will influence the success of biosimilars/follow-on biologics market. Enabling you with a platform to discuss the issues affecting the market, such as product selection and payer acceptance in a broader industry context. Consideration will be given to the evaluation of unwanted immunogenicity of follow-on biologicals, from preclinical development, through clinical trials, and into the post-registration period to minimise the risks associated with immunogenicity in recipients of therapeutic products.
This meeting has received excellent feedback in previous years and this year’s programme will be no exception. Key Speakers include:
Dr Rustom Mody, Director& Head Rategic Research, R&D and Quality, Intas Biopharmaceuticals
Lore Unt, Counsel for Intellectual Property Federal Trade Commission (FTC)
James Harris, Chief Effective Officer, Healthcare Economics
Elona Baum, Director, Policy and Management Operations, Regulatory/Quality/Compliance, Genentech
Linda R. Horton, Partner, Hogan & Hartson
Diane Edquist Dorman, Vice President for Public Policy, National Organization for Rare Disorders (NORD)
Marc Martens, Senior Associate, Bird & Bird
Dr Arnon Chait, President and CEO, Analiza
Dr Antony C Tridico, Partner, Biotechnology/Pharmaceutical Pratice Group, Finnegan Henderson
Robin Howard, Director, Simon–Kucher & Partners
Cecil Nick, Principal Consultant, Parexel
Dr Jacco Keja, Managing Director and Practice Leader, Quintiles Global Consulting Services
Key reasons you need to attend this event
Identify the trends that will shape future market development of follow-on biologics
Explore the current market and regulatory environment for biosimilars in Europe and the relevance to US legislation
Examine the emerging market landscape for biosimilars in India
Understand interchangeability/substitutibility policies
Discuss unwanted immunogenicity issues for biosimilars
Analyse the market impact of biosimilars from the Payers perception
Examine the pre-marketing hurdles and post-marketing challenges faced by biosimilar/follow-on biologics developers
Utilise new and established analytical tools for demonstrating comparability
Assess how is the landscape evolving for biosimilar medicines
Discuss Add this link to... Bury
This meeting has received excellent feedback in previous years and this year’s programme will be no exception. Key Speakers include:
Dr Rustom Mody, Director& Head Rategic Research, R&D and Quality, Intas Biopharmaceuticals
Lore Unt, Counsel for Intellectual Property Federal Trade Commission (FTC)
James Harris, Chief Effective Officer, Healthcare Economics
Elona Baum, Director, Policy and Management Operations, Regulatory/Quality/Compliance, Genentech
Linda R. Horton, Partner, Hogan & Hartson
Diane Edquist Dorman, Vice President for Public Policy, National Organization for Rare Disorders (NORD)
Marc Martens, Senior Associate, Bird & Bird
Dr Arnon Chait, President and CEO, Analiza
Dr Antony C Tridico, Partner, Biotechnology/Pharmaceutical Pratice Group, Finnegan Henderson
Robin Howard, Director, Simon–Kucher & Partners
Cecil Nick, Principal Consultant, Parexel
Dr Jacco Keja, Managing Director and Practice Leader, Quintiles Global Consulting Services
Key reasons you need to attend this event
Identify the trends that will shape future market development of follow-on biologics
Explore the current market and regulatory environment for biosimilars in Europe and the relevance to US legislation
Examine the emerging market landscape for biosimilars in India
Understand interchangeability/substitutibility policies
Discuss unwanted immunogenicity issues for biosimilars
Analyse the market impact of biosimilars from the Payers perception
Examine the pre-marketing hurdles and post-marketing challenges faced by biosimilar/follow-on biologics developers
Utilise new and established analytical tools for demonstrating comparability
Assess how is the landscape evolving for biosimilar medicines
Discuss Add this link to... Bury
Comments